Blue Sky Uranium Expands Drill Plan to Advance the Ivana Uranium-Vanadium Project
Frankfurt Stock Exchange: MAL2
OTCQB Venture Market (OTC): BKUCF
VANCOUVER, BC, May 14, 2025 /CNW/ - Blue Sky Uranium Corp. (TSXV: BSK) (FSE: MAL2) (OTC: BKUCF), ("Blue Sky" or the"Company") is pleased to announce an update to the 2025 drill program to advance the Ivana Uranium-Vanadium deposit towards feasibility. The drill program is being planned and executed by Blue Sky's joint-venture operating company Ivana Minerales S.A., (" JVCO", a partnership with Abatare Spain, S.L.U.).
The updated programs have led to a doubling of the original budget to US$6.0M, beyond the minimum annual commitment of US$3M for the first year stipulated in the joint-venture agreement. The new estimate includes US$4.4M for the infill drilling program and US$1.6M for a subsequent exploration drilling program.
Nikolaos Cacos, President & CEO of the Company stated, "It is clear that JVCO has decided to move forward with an aggressive work plan aimed at achieving technical and economic feasibility in the shortest possible time. This supports the near-term goal for Ivana: building a strong asset for our shareholders that offers Argentina a potential domestic uranium supply for its nuclear energy generation."
As previously reported, the next program is expected to include up to 6,000 metres of reverse circulation (" RC") drilling. The program has been refined to include approximately 330 drill holes with an estimated average depth of 18 metres as shown in Figure 1. This will include infill drilling to support the reclassification of some inferred mineral resources to indicated mineral resources and to improve the geological modeling to allow the design of the deposit to be adjusted for mining. A second phase RC drill program of up to 2,500 metres now been planned to follow the infill program. This program will test at least two new high-potential exploration targets surrounding Ivana.
Drilling proposals are currently being evaluated, and the JVCO team is prioritizing the availability of equipment and the possibility of having two rigs drilling simultaneously to accelerate the work plan.
The Company expects the drill program to begin this fiscal quarter once the final technical, legal and community requirements have been completed.
In addition to planning the drill program, the JVCO technical team is continuing its process of evaluating engineering companies capable of advancing the other technical and economic aspects of the project toward feasibility. In adherence to the principles of both joint-venture participants, the winning bid will offer the highest standards of modern and sustainable mining, extensive local experience, the ability and assurance of meeting the proposed goals within the required timeline and a commitment to an appropriate budget.
Qualified Persons
The technical contents of this news release have been reviewed and approved by Mr. Ariel Testi, CPG, who works for the Company and is a Qualified Person as defined in National Instrument 43-101.
About Ivana Minerales S.A.
Ivana Minerales S.A. is the operating company for the joint-venture between Blue Sky and its partner Abatare Spain, S.L.U. (" COAM") to advance the Ivana Uranium-Vanadium deposit in Rio Negro Province of Argentina. The activities of JVCO are subject to the earn-in transaction (the " Agreement") in which COAM will fund cumulative expenditures of US$35 million to acquire a 49.9% indirect equity interest in the Ivana deposit, and then has the further right to earn up to an 80% equity interest in JVCO by completion of a feasibility study and funding the costs and expenditures up to US$160,000,000 to develop and construct the project to commercial production, subject to the terms and conditions in the Agreement. For additional details, please refer to the News Release dated February 27, 2025, as well as the Company's latest Financial Statements & MD&A available at blueskyuranium.com.
About Blue Sky Uranium Corp.
Blue Sky Uranium Corp. is a leader in uranium discovery in Argentina. The Company's objective is to deliver exceptional returns to shareholders by rapidly advancing a portfolio of surficial uranium deposits into low-cost producers, while respecting the environment, the communities, and the cultures in all the areas in which we work. Blue Sky has the exclusive right to properties in two provinces in Argentina. The Company's Amarillo Grande Project was an in-house discovery of a new district that has the potential to be both a leading domestic supplier of uranium to the growing Argentine market and a new international market supplier. Blue Sky is advancing its flagship Ivana Uranium-Vanadium Deposit through a joint venture with subsidiaries of Corporación América Group. The Company is a member of the Grosso Group, a resource management group that has pioneered exploration in Argentina since 1993.
ON BEHALF OF THE BOARD
"Nikolaos Cacos"
_____________________________________
Nikolaos Cacos, President, CEO and Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements and forward-looking information (collectively, the "forward-looking statements") within the meaning of applicable securities laws. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "will", "estimates", "believes", "intends" "expects" and similar expressions which are intended to identify forward-looking statements. More particularly and without limitation, this press release contains forward-looking statements that, other than statements of historical fact, address activities, events or developments the Company believes, expects or anticipates will or may occur in the future, including, without limitation, statements about the Company's planned drilling campaign at the Ivana deposit and the timing thereof and the prospective nature of the "Bajo Huenteleo" target area. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things: uncertainty relating to mineral resources; risks related to heavy metal and transition metal price fluctuations, particularly uranium and vanadium; ri sks relating to the dependence of the Company on key management personnel and outside parties; the potential impact of global pandemics; risks and uncertainties related to governmental regulation and the ability to obtain, amend, or maintain licenses, permits, or surface rights; risks associated with technical difficulties in connection with mining activities; and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations, including in respect of the Company's planned drilling program described in this news release. Actual results may differ materially from those currently anticipated in such statements. Readers are encouraged to refer to the Company's public disclosure documents for a more detailed discussion of factors that may impact expected future results. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by securities law.
SOURCE Blue Sky Uranium Corp.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
15 minutes ago
- Toronto Star
PharmaCorp Rx Inc. Reports Q2 2025 Financial Results
SASKATOON, Saskatchewan, Aug. 15, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. ('PharmaCorp' or the 'Corporation') (TSXV: PCRX) a growing national platform for pharmacist-led community pharmacy ownership, today reported its financial results for the three and six months ended June 30, 2025. The second quarter reflected continued operational momentum, expanding pharmacy-level contribution, and disciplined progress on the Corporation's national acquisition strategy. Following quarter-end, PharmaCorp completed the acquisition of a fourth pharmacy in Western Canada, building further scale and reinforcing the platform's coast-to-coast ambitions. Q2 2025 Financial Highlights Revenues generated from three operating pharmacies, with continued growth in both prescription volumes and front-of-store sales Operating infrastructure was successfully deployed to support national scalability, including systems integration, pharmacy onboarding, and co-ownership execution Net loss for the quarter reflects continued investment in corporate infrastructure and the catch-up of executive compensation deferred from 2024 Solid pharmacy-level contribution margins and a consistent weighted average EBITDA multiples across acquisitions support PharmaCorp's long-term accretive growth model A strong balance sheet positions the Corporation to fund additional acquisitions already under letter of intent Same-store sales, a supplementary financial measure, increased 11.3% year-over-year compared to Q2 2024, reflecting continued organic growth across our pharmacy network Prescription volumes continue to grow, with total script count rising 3.5% year-over-year compared to Q2 2024, demonstrating sustained patient engagement and activity across the network Management Commentary 'We are pleased with the momentum we're seeing across our early acquisitions and the continued appetite from independent pharmacy owners exploring succession,' said Alan Simpson, Executive Chairman of PharmaCorp. 'This quarter reflects continued progress in scaling our platform through disciplined execution. We continue to maintain a consistent, disciplined weighted average EBITDA multiple across our acquisitions, which supports our goal of delivering accretive growth. As we expand our national footprint, we remain focused on sourcing high-quality pharmacies that align with our long-term acquisition strategy and contribute meaningfully to accretion.' ARTICLE CONTINUES BELOW Operational Update During the quarter, the Corporation made key investments in systems, personnel, and integration processes necessary to support scalable national growth. The reported net loss includes compensation charges related to deferred 2024 executive remuneration, which were brought current in Q2 as part of aligning leadership incentives with long-term shareholder value. Subsequent Events On July 31, 2025, the Corporation closed the acquisition of its fourth pharmacy, located in Western Canada, further expanding its national footprint and operating base under the PharmaCorp co-ownership platform. On August 13, 2025, the Corporation entered into a credit agreement with Canadian Imperial Bank of Commerce ('CIBC') providing the Corporation with up to $20,500,000 of committed credit facilities (the 'Credit Facilities'), plus a $10,000,000 accordion feature and a $1,000,000 Visa credit facility. The Credit Facilities will support PharmaCorp's acquisition strategy and the expansion of its acquisition and operating platforms. In conjunction with the above Credit Facilities, CIBC is also supporting PharmaCorp's Pharmacist Co-Ownership Program through a separate $5,000,000 credit facility which makes loans available to pharmacists wishing to acquire an ownership position in the PharmaCorp pharmacy where they work. Pipeline Progress PharmaCorp continues to advance its previously announced pipeline of transactions. The Corporation is actively working to finalize definitive purchase and sale agreements in furtherance of the letters of intent announced on May 29, 2025, and expects to close additional transactions in the second half of the year. Further Information For comprehensive disclosure of PharmaCorp's financial performance for the three and six months ended June 30, 2025 and its financial position as at such date, please see PharmaCorp's unaudited Condensed Consolidated Interim Financial Statements and related Management's Discussion and Analysis for the three and six months ended June 30, 2025 filed on SEDAR+ at Supplementary Financial Measures This news release also makes reference to 'same-store sales', which is a supplementary financial measure. 'Same-store sales' is defined as sales from pharmacy locations owned and operated by PharmaCorp as at the current reporting period end and historical sales information from the pharmacies operating systems. It is used to provide investors with a supplemental measure of the Corporation's operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management uses supplementary financial measures such as same-store sales in order to facilitate operating performance comparisons from period to period. Management also believes that supplementary financial measures are meaningful to investors because they enable investors to better understand the level of growth of our business. The Corporation cautions readers that same-store sales used in this news release may not be comparable to similar measures used by other issuers. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW About PharmaCorp Rx Inc. PharmaCorp Rx Inc. is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists to become equity partners while supporting continuity of care and succession for retiring pharmacy owners. PharmaCorp combines operational support, capital, and strategic guidance to build a national network of locally rooted community pharmacies. PharmaCorp currently operates four PharmaChoice Canada bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada branded pharmacies as they come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The Corporation will also acquire independently owned non-PharmaChoice Canada bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner. PharmaCorp shares trade on the TSX Venture Exchange under the symbol: PCRX. PharmaCorp actively welcomes discussions with pharmacy owners considering succession or sale. For more information about our acquisition program and process, please visit or contact our team confidentially. We are committed to seamless transitions that protect your legacy and serve your community. For further information, please contact: Investor Relations info@ Tel: (306) 536-3771 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains 'forward-looking information' regarding the Corporation within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the Corporation's continued operational momentum, expanding pharmacy-level contribution, and disciplined progress on the Corporation's national acquisition strategy; the Corporation's coast-to-coast platform and acquisitions ambitions; the Corporation's long-term accretive growth model; the funding available for acquisitions already under letters of intent; the continued appetite from independent pharmacy owners exploring succession; the Corporation's goal of delivering accretive growth; the Corporation's focus on sourcing high-quality pharmacies that align with its long-term acquisition strategy and contribute meaningfully to accretion; the Credit Facilities, including the accordion feature, the impact of the Credit Facilities on the Corporation's acquisition strategy and its acquisition and operating platforms; the Pharmacist Co-Ownership Program including the $5,000,000 credit facility to support the program, the availability of the $5,000,000 credit facility and the terms of this credit facility; the Corporation's work to finalize definitive purchase and sale agreements in furtherance of previously announced letters of intent; the Corporation's expectation to close additional transactions in the second half of the year; and the Corporation's goal to continue to acquire pharmacies as they come to market and to operate such pharmacies under the PharmaChoice Canada banner. This forward-looking information reflects current beliefs and is based on information currently available to the management of the Corporation and on assumptions the Corporation believes are reasonable. These assumptions include, but are not limited to: the completion of previously announce acquisitions; market acceptance of previously announced acquisitions; the continued appetite from independent pharmacy owners exploring succession; market acceptance of the Pharmacist Co-Ownership Program and the terms of the credit facility under such program; the volume of acquisition opportunities presented to the Corporation being equal to or greater than historical volumes; and the continued supply of pharmacies for purchase by the Corporation at prices satisfactory to the Corporation and the ability of the Corporation to acquire such pharmacies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board of directors, third party or regulatory approvals; competition; changes in legislation, including pharmacy regulation, affecting the Corporation; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; and lack of qualified, skilled labour or loss of key individuals. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Corporation's disclosure documents on the SEDAR+ website at Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of the Corporation as of the date of this news release and, accordingly, is subject to change after such date. However, the Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Toronto Star
15 minutes ago
- Toronto Star
Water Ways Announces Effective Date of Share Consolidation and Provides Corporate Update
TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) ('Water Ways' or the 'Company'), is pleased to announce that further to its news release dated June 18, 2025, the Company has received final acceptance from the TSX Venture Exchange (the 'TSXV') of the consolidation of its outstanding common shares (the 'Common Shares') on the basis of one (1) post-consolidation Common Share for every ten (10) pre-consolidation Common Shares (the 'Share Consolidation'). Effective at the opening of trading on August 21, 2025 (the 'Effective Date'), the Common Shares will commence trading on the TSXV on a consolidated basis. As a result of the Share Consolidation, the 148,785,346 issued and outstanding Common Shares will be reduced to approximately 14,878,537 Common Shares. No fractional Shares will be issued, and any post consolidated fraction of a Common Share will be rounded to the nearest whole number. The exercise or conversion price and the number of Common Shares issuable under any of the Company's outstanding convertible instruments will be proportionately adjusted on the Effective Date in accordance with their terms.
National Post
15 minutes ago
- National Post
Canadians' view of leadership in Washington plunges: Gallup poll
In the wake of a stormy stretch in Canada-U.S. relations, the Canadian view of American leadership has plummeted. Article content Gallup's latest survey of Canadian opinion, conducted in May and June, found approval of Washington slipping to 15 per cent, statistically in line with sentiment when Donald Trump was president the first time. Article content Article content Canadian opinion of leaders in Washington has fluctuated over time, showing a clear connection with who is sitting in the White House. For example, Canadian approval of American leadership averaged 61 per cent under Barack Obama, compared with 19 per cent in Trump's first term and 41 per cent under Joe Biden. Article content Aside from an uptick in 2021, only a minority of Canadians have approved of Washington since 2017. Article content Article content The latest downturn comes in the midst of diplomatic and trade tensions. Since returning to the White House, Trump has introduced high tariffs and continued with rhetoric suggesting Canada should become the '51st state.' Article content Gallup asked about four global powers during it recent World Poll. Germany's leadership received the most positive ratings from Canadians. A slim majority of Canadians (54 per cent) approve of Berlin. Article content Canadians have a higher approval rating for Beijing than they do for Washington. It sits at 23 per cent, up eight points from last year's poll. Article content Otherwise, the 79 per cent of Canadians who disapprove of U.S. leadership is statistically close to the 82 per cent who disapprove of Russia's. Article content Meanwhile, Canadians' view of their own leadership has improved considerably, rising 19 points from last year to 59 per cent now. The increase followed Mark Carney replacing Justin Trudeau as Liberal party leader and prime minister in March and his election victory in April. Article content Article content Approval of Trudeau fell from 64 per cent in 2016 — his first full year in office — to a low of 40 per cent in 2024. Article content Article content However, Canadians are gloomy about the state of the economy. Their optimism dropped to a new low in 2025, with 27 per cent saying their local economy is getting better, compared to 63 per cent who think it's getting worse. Article content The share of Canadians who say it's a good time to find a new job has fallen sharply down from 74 per cent in 2022 to 32 per cent in 2025. This is the lowest level of job optimism since the COVID-19 pandemic started in 2020 and the 2009 financial crisis. Article content The housing affordability crisis also remains widespread in Canada. One in four adults are satisfied with the availability of good, affordable housing, compared with 72 per cent who are dissatisfied. Article content Weak economic sentiment poses a test for Carney, says the folks at Gallup. 'Sustaining public support may depend on whether his administration can reverse declining optimism and navigate a complicated relationship with Washington.' Article content
